Is Sera Prognostics Inc (SERA) overvalued? · rev $77.0K
Sera Prognostics Inc (SERA) is a medical devices company listed on US.
This page asks whether Sera Prognostics Inc (SERA) looks expensive on cached numbers — not a short thesis.
Latest reported SERA revenue for 2024-12-31 was $77.0K. Net income was -$32.9M. Revenue was down 74.8% from 2023-12-31 to 2024-12-31. SERA currently screens at market cap $89.1M.
SERA currently screens at market cap $89.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SERA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SERA stock page for the full model, not this heading.
Not investment advice.